The SGLT-2 inhibitors class represents a critical new therapeutic approach for preventing heart failure in at-risk patients with T2DM and is actively being studied for use in treating patients with heart failure, with or without T2DM [4]. Here, SLC5A2 is linked to type 2 diabetes mellitus.